| Literature DB >> 33580050 |
David Pejoski1,2, Casimir de Rham1,3, Paola Martinez-Murillo1,2, Francesco Santoro4, Floriane Auderset1,2, Donata Medaglini4, Gianni Pozzi4, Maria Vono1,2, Paul-Henri Lambert1,2, Angela Huttner2,5, Mariëlle C Haks6, Tom H M Ottenhoff6, Jean Villard1,3, Claire-Anne Siegrist7,8.
Abstract
The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56+ NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)+ cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR+ CD56dim or cytokine-responsive CD56bright NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans.Year: 2020 PMID： 33580050 DOI： 10.1038/s41541-020-0179-4
Source DB: PubMed Journal: NPJ Vaccines ISSN： 2059-0105 Impact factor: 7.344